U.S. FDA Requirements: Lisdexamfetamine Dimesylate
Pharmaceutical / Drug Definition :
Rapidly absorbed and converted to dextroamphetamine, which is responsible for CNS activity. Therapeutic action in attention deficit hyperactivity disorder (ADHD) is unknown.
FDA Label Requirements and Exceptions
Lisdexamfetamine Dimesylate
FDA Import Information
Lisdexamfetamine Dimesylate
FDA Detentions
Lisdexamfetamine Dimesylate (Lisdexamfetamine Dimesylate Entry Refusal)
General U.S. Food and Drug Administration Guidelines for:
- Manufacturers Lisdexamfetamine Dimesylate (Lisdexamfetamine Dimesylate Suppliers)
- Processors Lisdexamfetamine Dimesylate
- Repackers Lisdexamfetamine Dimesylate
- Relabelers Lisdexamfetamine Dimesylate
- Exporters Lisdexamfetamine Dimesylate
- Importers Lisdexamfetamine Dimesylate
For more information about Lisdexamfetamine Dimesylate, simply click below:
U.S. FDA Regulations:
U.S. FDA Regulation: 21 C.F.R. Part 207
Registrar Corp assists businesses with U.S. FDA compliance. Certificates of Registration issued by Registrar Corp provide confirmation to industry that you are fulfilling U.S. FDA registration requirements. U.S. FDA does not issue or recognize Certificates of Registration. Registrar Corp is not affiliated with the U.S. Food and Drug Administration.
